'Lilly's Taltz plus Zepbound shows superior efficacy in phase 3b trial for arthritis, obesity'

 At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to ≥10% weight reduction with concomitant Taltz and Zepbound compared to Taltz monotherapy  

In a key secondary endpoint, use of Taltz and Zepbound delivered a 64% relative increase in the proportion of patients achieving ACR50 compared to Taltz alone (33.5% of patients vs. 20.4%, p<.05)

Taltz is now the first and only biologic for PsA with data supporting a potential comprehensive treatment approach alongside an incretin therapy for patients who also have obesity (BMI ≥30 kg/m²) or overweight (BMI 27-29.9 kg/m²) with at least one weight-related condition

https://www.prnewswire.com/news-releases/lillys-taltz-ixekizumab-and-zepbound-tirzepatide-used-together-delivered-superior-efficacy-in-first-of-its-kind-phase-3b-trial-for-adults-with-active-psoriatic-arthritis-and-obesity-or-overweight-302656726.html